Sarepta Therapeutics (SRPT) Enterprise Value (2010 - 2026)

Sarepta Therapeutics' Enterprise Value history runs 17 years deep, the most recent figure standing at -$685.0 million for Q1 2026.

• In Q1 2026, Enterprise Value fell 31.04% year-over-year to -$685.0 million; the TTM figure through Mar 2026 stood at -$685.0 million (down 31.04% YoY), while the FY2025 annual figure was -$853.0 million, up 37.04% from the prior year.
• Enterprise Value was -$685.0 million for Q1 2026 at Sarepta Therapeutics, up from -$853.0 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$522.8 million in Q1 2025 to a low of -$2.1 billion in Q3 2022.
• Historically, Enterprise Value has averaged -$1.4 billion across 5 years, with a median of -$1.5 billion in 2024.
• The sharpest annual moves came in 2025 and 2026: Enterprise Value surged 62.41% in 2025, then sank 31.04% in 2026.
• A 5-year view of Enterprise Value shows it stood at -$2.0 billion in 2022, then grew by 15.74% to -$1.7 billion in 2023, then rose by 19.18% to -$1.4 billion in 2024, then jumped by 37.04% to -$853.0 million in 2025, then increased by 19.69% to -$685.0 million in 2026.
• The last three Enterprise Value figures came in at -$685.0 million (Q1 2026), -$853.0 million (Q4 2025), and -$642.5 million (Q3 2025), per Business Quant data.